Emcure pharmaceuticals walk-in on 26th May 2024 for QA, QC, Production, Engineering, warehouse
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Pune. Emcure’s product portfolio includes tablets, capsules (both softgel capsules and hard-gel capsules) and injectables. The company is a major producer of HIV antivirals, as well as gynaecology and blood therapeutic drugs.
This is the list of manufacturing facilities based in India – Solid Dosage facility at Hinjwadi – In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets, but is under FDA warning letter. Small volume parenteral facility at Hinjawadi – US FDA, UK MHRA approved. Has lyophilization and pfs capability, but is under FDA warning letter. Oncology injectable facility at Hinjawadi, but is under FDA warning letter. Solid Orals facilities at Jammu and Bhosari. API facility at Kurkumbh- US FDA approved. Biotech facility at Hinjawadi. R&D Center at Gandhinagar and plant at Sanand, Ahmedabad.- Sanand facility is US FDA approved. US plant .USA – The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA.Emcure voices its concerns on HIV/AIDS through its “Let’s fight AIDS together” initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports ‘Taal’, a pharmacy for HIV/AIDS patients run by HIV/AIDS patients. Emcure has license agreements with Bristol-Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir as part of their Global Access Programs.Heritage Pharmaceuticals, a former division of Emcure, entered into a deferred prosecution agreement[13] with the United States Department of Justice, Antitrust Division (“DOJ”) relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage agreed to pay a $225,000 fine. The DPA expired on May 30, 2022, and the United States District Court for the Eastern District of Pennsylvania dismissed with prejudice the one-count Information filed by the DOJ against Heritage on June 30, 2022.
More about company
Vacancy details –
Department – QA, QC, Production, Engineering, warehouse
Qualification – M pharm, B pharm, Msc, Bsc, ITI, Diploma, D Pharma, BE, B tech , Graduate
Experience – 2 to 6 years
Similar job’s
Sun Pharma walk-in on 18th & 19th May 2024
This is the list of manufacturing facilities based in India – Solid Dosage facility at Hinjwadi – In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets, but is under FDA warning letter. Small volume parenteral facility at Hinjawadi – US FDA, UK MHRA approved. Has lyophilization and pfs capability, but is under FDA warning letter. Oncology injectable facility at Hinjawadi, but is under FDA warning letter. Solid Orals facilities at Jammu and Bhosari. API facility at Kurkumbh- US FDA approved. Biotech facility at Hinjawadi. R&D Center at Gandhinagar and plant at Sanand, Ahmedabad.- Sanand facility is US FDA approved. US plant .USA – The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA.Emcure voices its concerns on HIV/AIDS through its “Let’s fight AIDS together” initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports ‘Taal’, a pharmacy for HIV/AIDS patients run by HIV/AIDS patients. Emcure has license agreements with Bristol-Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir as part of their Global Access Programs.Heritage Pharmaceuticals, a former division of Emcure, entered into a deferred prosecution agreement[13] with the United States Department of Justice, Antitrust Division (“DOJ”) relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage agreed to pay a $225,000 fine. The DPA expired on May 30, 2022, and the United States District Court for the Eastern District of Pennsylvania dismissed with prejudice the one-count Information filed by the DOJ against Heritage on June 30, 2022.
Important details –
Location – Sikkim
Selection process – The selection will be on the basis of interview
Mode of interview – Face to face
Interview rounds of interview – HR
Walk-in interview details –
Date – 26th May 2024
Time – 09:30 Am to 04:00 Pm
Venue – Emcure pharmaceuticals Ltd, 3rd mile, rangpo – rorathang road, Block- kamarey Bhasmey Elaka- Pakyong Rangpo , East Sikkim 737132
Note –
Please bring photocopies of all your relevant documents like CTC proof, Education etc.
Send resume to HR mail – hr.plant@zuventus.com bhawana.mukkhia@zuventus.com
For more job related updates joined WhatsApp group
https://chat.whatsapp.com/KCk1lRtEdlJEJYDBTQNc9i